Don’t Miss National Eosinophil Awareness Week!

It's time to raise awareness for and celebrate the patient population that lives with eosinophilic disorders. From May 15th until the 21st, the American Partnership for Eosinophilic Disorders (APFED) is…

Continue Reading Don’t Miss National Eosinophil Awareness Week!
“New Era for Preventing End-Stage Kidney Disease Act” Could Improve Rare Disease Kidney Care
source: pixabay.com

“New Era for Preventing End-Stage Kidney Disease Act” Could Improve Rare Disease Kidney Care

The New Era for Preventing End-Stage Kidney Disease Act (H.R. 7506) is a new Act sponsored by Reps Gus Bilirakis and G.K. Butterfield. This Act would transform care for those…

Continue Reading “New Era for Preventing End-Stage Kidney Disease Act” Could Improve Rare Disease Kidney Care

Rare Disease Clinical Trials Are Essential to Help Uncover Potential Patient Solutions: Spotlight on Classic Congenital Adrenal Hyperplasia (CAH)

Acknowledgment: This story is sponsored by Neurocrine Biosciences and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted,…

Continue Reading Rare Disease Clinical Trials Are Essential to Help Uncover Potential Patient Solutions: Spotlight on Classic Congenital Adrenal Hyperplasia (CAH)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study

[Cancer Management and Research](cancer-management-and-research-journal) » [Volume 14](cancer-management-and-research-archive55-v1655) Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study Authors [Zhang S](author_profile.php?id=1654738)…

Continue Reading Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
May is Amyotrophic Lateral Sclerosis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

May is Amyotrophic Lateral Sclerosis Awareness Month: Spreading Rare Disease Awareness

According to a story from ALS News Today, around 5,000 people get diagnosed with amyotrophic lateral sclerosis (ALS) annually. In addition, costs of treatment for patients average $250,000 out of…

Continue Reading May is Amyotrophic Lateral Sclerosis Awareness Month: Spreading Rare Disease Awareness
Cornelia de Lange (CDLS) Syndrome Awareness day is May 14th and Support is Needed Now More Than Ever
source: pixabay.com

Cornelia de Lange (CDLS) Syndrome Awareness day is May 14th and Support is Needed Now More Than Ever

  It is believed that in 1916 a German doctor named Brachmann first identified a patient with symptoms of a disease later known as Cornelia de Lange syndrome. Then in…

Continue Reading Cornelia de Lange (CDLS) Syndrome Awareness day is May 14th and Support is Needed Now More Than Ever
Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
https://pixabay.com/en/hand-world-ball-keep-child-earth-644145/

Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…

Continue Reading Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment
jarmoluk / Pixabay

Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment

Aeterna Zentaris’s ongoing DETECT trial is evaluating the drug macimorelin (tradename Macrilen™) for childhood-onset growth hormone deficiency (CGHD). As recently announced in an article published by GlobeNewsWire, the study (AEZS-130-PO2),…

Continue Reading Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment

A New Standard for Corticosteroid Dosing for Childhood-Onset SLE with Proliferative Lupus Nephritis

Recently, an international group of pediatric rheumatologists and nephrologists met and created a consensus on a standard for a steroid-dosing regimen to treat childhood-onset systemic lupus erythematosus with proliferative lupus…

Continue Reading A New Standard for Corticosteroid Dosing for Childhood-Onset SLE with Proliferative Lupus Nephritis
FDA Approved: Cuvrior for Wilson Disease
https://unsplash.com/photos/_jbClosDsD4

FDA Approved: Cuvrior for Wilson Disease

For the last 52 years, individuals with Wilson disease have been relying, largely, on the same treatment options. These options, designed to remove copper from the body, include Cuprimine (penicillamine).…

Continue Reading FDA Approved: Cuvrior for Wilson Disease

A Mother’s Thoughts When Her Two-Year-Old Daughter Was Diagnosed with Acute Lymphoblastic Leukemia

Imagine the highs and lows that accompany the doctor’s announcement that your sweet, innocent two-year-old daughter has leukemia. The good news is that your daughter has the type of leukemia…

Continue Reading A Mother’s Thoughts When Her Two-Year-Old Daughter Was Diagnosed with Acute Lymphoblastic Leukemia